Zosuquidar (LY335979) 3HCl: Selective P-gp Inhibitor for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a selective inhibitor of the ATP-dependent efflux transporter P-glycoprotein (P-gp), which mediates multidrug resistance (MDR) in cancer by reducing intracellular concentrations of chemotherapeutics (APExBIO product page). At low micromolar concentrations, Zosuquidar restores sensitivity to agents such as vinblastine and doxorubicin in P-gp-overexpressing tumor lines (Sun et al., 2025). The compound demonstrates efficacy in both in vitro and in vivo models without altering drug pharmacokinetics. Clinical trials in non-Hodgkin's lymphoma and solid tumors show effective P-gp inhibition with minimal toxicity. Zosuquidar is stable in DMSO and intended for storage at -20°C; solutions should not be stored long-term.

Biological Rationale

P-glycoprotein (P-gp, ABCB1) is an ATP-dependent efflux pump that transports a wide range of xenobiotics and chemotherapeutics out of cells (Sun et al., 2025). It is highly expressed in tissues such as the brain, liver, intestine, and various cancer cells. Overexpression of P-gp is a major mechanism of multidrug resistance (MDR) in cancer. P-gp limits the intracellular accumulation of cytotoxic drugs, leading to reduced efficacy of chemotherapy. Inhibiting P-gp function restores drug sensitivity and enhances the effectiveness of standard chemotherapeutic regimens. Reversal of P-gp-mediated drug resistance is a validated strategy for overcoming treatment failure in cancers such as acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (see prior summary).

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl is a competitive inhibitor that binds to the substrate binding site of human P-gp, blocking the efflux of chemotherapeutic agents such as vinblastine, doxorubicin, etoposide, and paclitaxel. The binding is reversible and selective for P-gp, with reported half-maximal inhibitory concentration (IC₅₀) values typically in the low micromolar range under standard cell culture conditions (37°C, pH 7.4). Zosuquidar does not significantly inhibit other ATP-binding cassette (ABC) transporters at these concentrations (Sun et al., 2025). In intact cells, Zosuquidar rapidly restores intracellular drug accumulation, leading to enhanced cytotoxicity of P-gp substrate drugs. The compound does not alter the pharmacokinetics of co-administered chemotherapy agents in animal models, minimizing drug-drug interaction risks. Its selectivity reduces off-target toxicity compared to first-generation inhibitors (see protocol-focused article for contrast).

Evidence & Benchmarks

• In vitro, Zosuquidar at 0.1–1 μM fully blocks P-gp-mediated efflux of calcein-AM and rhodamine 123 in leukemia cell lines (Sun et al., 2025, DOI).
• Co-treatment with Zosuquidar (1 μM) restores vinblastine, doxorubicin, etoposide, and paclitaxel sensitivity in P-gp overexpressing tumor cell lines, reducing IC₅₀ values by 10–30 fold (Sun et al., 2025, DOI).
• In vivo, Zosuquidar (10 mg/kg, i.p.) enhances antitumor activity and prolongs survival in murine models of MDR leukemia and non-small cell lung carcinoma xenografts without affecting plasma pharmacokinetics of chemotherapeutics (Sun et al., 2025, DOI).
• Phase I/II clinical trials using Zosuquidar (LY335979) with CHOP or vinorelbine regimens in non-Hodgkin's lymphoma and advanced solid tumors report effective P-gp inhibition with minimal added toxicity (Sun et al., 2025, DOI).
• Zosuquidar maintains selectivity for P-gp and does not significantly inhibit CYP450 enzymes at pharmacologically relevant concentrations (Sun et al., 2025, DOI).

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is validated for the reversal of P-gp-mediated MDR in cancer cell lines and animal models. It is used to sensitize acute myeloid leukemia (AML) cells and solid tumors to chemotherapeutics. The compound is a valuable research tool for dissecting MDR mechanisms and validating P-gp transport assays. In clinical settings, Zosuquidar is evaluated as an adjunct to standard chemotherapy for MDR cancers. However, P-gp-independent mechanisms of resistance (e.g., MRP1/ABCC1, BCRP/ABCG2, or mutations in drug targets) are not addressed by Zosuquidar.

Common Pitfalls or Misconceptions

• Zosuquidar is not effective against non–P-gp-mediated drug resistance (e.g., resistance due to MRP1 or BCRP overexpression).
• The inhibitor does not reverse resistance caused by target mutations or enhanced DNA repair mechanisms.
• Solution stability is limited; pre-dissolved stocks in DMSO should not be stored long-term due to degradation risk.
• Zosuquidar does not significantly inhibit hepatic CYP450 enzymes, so it is not suitable for CYP-mediated drug-drug interaction studies.
• It is not a general chemosensitizer and should be used only where P-gp is a validated resistance factor.

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl (SKU A3956) from APExBIO is supplied as a solid for reconstitution in DMSO. Recommended working concentrations in cell-based assays are 0.1–1 μM. For animal studies, 10 mg/kg (intraperitoneal) is commonly used. Store lyophilized material at -20°C; avoid repeated freeze-thaw cycles. Solutions in DMSO should be prepared fresh before use. In co-treatment protocols, add Zosuquidar to media 15–30 minutes before chemotherapeutic agents. For P-gp activity assays, use established fluorescent substrates (e.g., calcein-AM, rhodamine 123) and monitor intracellular retention. For more scenario-driven workflows, see this evidence-based guide—this article extends those practical protocols by clarifying clinical and pharmacokinetic boundaries.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a benchmark P-gp inhibitor for multidrug resistance reversal in preclinical and translational research. Its selectivity, potency, and pharmacokinetic neutrality make it suitable for both mechanistic and applied studies. Ongoing clinical evaluation may further expand its utility in combination therapy for MDR cancers. For detailed product specifications, visit the Zosuquidar (LY335979) 3HCl product page from APExBIO. For advanced translational strategies, this review provides a strategic roadmap—this article updates those recommendations with the latest pharmacokinetic and clinical data.